NIHR Clinical Research Network NIHR Local Clinical Research Network Funding Allocations 2016/17
NIHR Clinical Research Network Coordinating Centre 25 April 2016 [Version 1.0]
Delivering research to make patients, and the NHS, better
NIHR LCRN Funding Allocations 2016/17 Public Version Contents 1.
INTRODUCTION ............................................................................................................................. 4
2.
LCRN FUNDING ............................................................................................................................. 5 2.1.
NIHR CRN Funding Allocation ................................................................................................ 5
2.2.
NIHR CRN Funding Allocation Model Elements ..................................................................... 5
2.3.
Element A: Top-sliced ............................................................................................................. 6
2.3.1.
Radiotherapy Trials Quality Assurance (RTTQA) ........................................................... 6
2.3.2.
Paediatric Pharmacy and Formulations .......................................................................... 7
2.3.3.
Chemotherapy and Pharmacy Advisory Service (CPAS) ............................................... 7
2.3.4.
NIHR CRN National Specialty Leadership ...................................................................... 7
2.3.5.
VAT ................................................................................................................................. 8
2.4.
Element B: Activity-based ....................................................................................................... 8
2.4.1.
Recruitment-related component ...................................................................................... 9
2.4.2.
Project-related component ............................................................................................ 12
2.5.
Element C: Performance-based ............................................................................................ 13
2.5.1.
Flow-through Funding ................................................................................................... 13
2.5.2.
CRN Performance Premium ......................................................................................... 14
2.6.
Element D: Population-based ............................................................................................... 15
2.7.
Element E: LCRN Host Corporate Support Services ............................................................ 15
2.8.
Element F: LCRN Leadership and Management .................................................................. 16
2.9.
Adjustments........................................................................................................................... 17
2.9.1.
NHS Market Forces Factor ........................................................................................... 17
2.9.2.
Cap and Collar .............................................................................................................. 18
2.9.3.
Data Mapping ................................................................................................................ 18
3.
TABLES......................................................................................................................................... 20
4.
APPENDICES ............................................................................................................................... 27 Appendix 1: Membership of NIHR CRN Funding Project Board & NIHR CRN Funding and Financial Management Steering Group ............................................................................................................ 27 Appendix 2: Past and Future Funding for the National RTTQA Group ............................................ 29 Appendix 3: Funding model for NIHR CRN National Specialty Leads / Co-Leads ........................... 31 Appendix 4: NIHR CRN National Specialty Leads funding 2015/16 and 2016/17............................ 33 Appendix 5: 2016/17 funding allocations for project-based element ................................................ 35 Appendix 6: Total Number of Sites Achieving Recruitment to Time and Target for Commercial Studies .............................................................................................................................................. 36 Appendix 7: Performance-based funding allocations 2016/17 ......................................................... 37 Appendix 8: Calculation of population-based funding allocations..................................................... 38 Appendix 9: Corporate Support Services funding allocations ........................................................... 39 Appendix 10: LCRN Leadership and Management funding allocations for each LCRN .................. 41 Appendix 11: 2016/17 MFF index per LCRN .................................................................................... 42 Appendix 12: Trust to LCRN mapping changes and resulting funding change .Error! Bookmark not defined.
2
NIHR LCRN Funding Allocations 2016/17 Public Version
3
NIHR LCRN Funding Allocations 2016/17 Public Version
1.
INTRODUCTION This document sets out the NIHR Local Clinical Research Network (LCRN) funding allocations for the 2016/17 financial year.
The total LCRN funding allocation for 2016/17 is £290.6m. This is equal to the sum of the ‘core funding’ allocation of £284.6m and an additional £6m provided specifically for the commercial incentivisation ‘flow-through’ element (see section 2.5.1).
In the course of 2015/16 the CRNCC has undertaken a review of each of the funding elements that constitute the LCRN funding model and a number of changes have been made in order to improve the model. These are documented in this paper. In addition we have taken a longer term view to help build in improvements beyond 2016/17. All changes to the LCRN funding model have been very carefully considered to ensure that we provide a level of stability for the LCRNs and the NIHR CRN workforce.
The LCRN funding model for 2016/17 has been produced by the NIHR CRN Funding Project Board, which includes representation from across the NIHR CRN national leadership and senior management, and is chaired by John Sitzia (CRN Chief Operating Officer). In addition, advice and strategic steer has been sought via the NIHR CRN Funding and Financial Management Steering Group. This group is primarily comprised of Finance representatives from LCRN Host organisations, acting on behalf of the networks. Please see a list of representatives for each of these groups in Appendix 1. The recommendations in this document have been approved by the NIHR CRN Executive Board.
4
NIHR LCRN Funding Allocations 2016/17 Public Version
2.
LCRN FUNDING
2.1.
NIHR CRN Funding Allocation The total CRN funding allocation for 2016/17 is £290.6m. This is equal to the sum of the historic ‘core funding’ allocation of £284.6m per annum and an additional £6.0m provided specifically for the commercial incentivisation ‘flowthrough’ element (see section 2.5).
2.2.
NIHR CRN Funding Allocation Model Elements The LCRN funding allocation model for 2016/17 comprises the following elements: ID
Element
A
Top-sliced
B
Activity-based
C D E F
Performancebased Population-based LCRN Host Corporate Support Services LCRN Leadership and Management
Description Funding to support specified centralised NHS Support activities that have national coverage, and NIHR CRN National Specialty Leads Allocation based on an LCRN’s recruitment and project-level activity Allocation based on an LCRN’s performance in the delivery of commercial contract research Allocation based on an LCRN’s resident population Funding to support the facilities and services that facilitate the governance, leadership and management of the LCRN Funding to meet the costs of specified LCRN leadership and management posts
A detailed justification for each element follows. The amounts and proportions of funding for each element are set out in the table below:
Allocation 2016/17 £2,040,806
% of Total 0.7%
£217,436,006
74.8%
Performance-based
£11,000,000
3.8%
Population-based
£43,000,000
14.8%
LCRN Leadership and Management
£12,017,490
4.1%
£5,105,698
1.8%
£290,600,000
100.0%
Element National (top-sliced) Activity-based
LCRN Corporate Support Services Total
5
NIHR LCRN Funding Allocations 2016/17 Public Version
2.3.
Element A: Top-sliced The top-sliced element is an allocation of funding to support specified centralised NHS Support activities that have national coverage, and also to provide for NIHR CRN National Specialty Leads. Funding for top-sliced elements is taken from the total NIHR CRN funding allocation before calculation of LCRN allocations.
The following services are funded in 2016/17:
Radiotherapy Trials Quality Assurance (RTTQA)
Paediatric Pharmacy and Formulations
NIHR CRN National Specialty Leads (previously known as NIHR CRN National Clinical Research Specialty Group Chairs)
2.3.1.
Chemotherapy & Pharmacy Advice Service (CPAS)
Radiotherapy Trials Quality Assurance (RTTQA) The allocation of £995,902 is provided for this service for 2016/17 (2015/16: £927,512).
As in previous years funding will be provided to Mount Vernon Cancer Centre (‘Mount Vernon’), part of East and North Hertfordshire NHS Trust and routed through CRN: Eastern, for the purposes of providing a national RTTQA programme for all NIHR CRN Portfolio studies that include a radiotherapy component. The service is provided by four centres working in partnership: (Mount Vernon, The Royal Marsden NHS Foundation Trust, Velindre NHS Trust and The Clatterbridge Cancer Centre NHS Foundation Trust). Service coordination and financial management of the allocation is provided by Mount Vernon.
Given the increase in the volume and complexity of radiotherapy trials, the RTTQA service has offered increasing value for money over the last three years. The CRNCC is mindful of the challenges associated with the Quality Assurance (QA) requirements for modern radiotherapy techniques including stereotactic radiotherapy, adaptive radiotherapy and brachytherapy, and emerging areas including proton therapy, MR-linac and molecular radiotherapy.
6
NIHR LCRN Funding Allocations 2016/17 Public Version
The CRN has approved an increase in the allocation for RTTQA from £927,512 in 2015/16 to £995,902 in 2016/17.
Please see Appendix 2 for further details.
2.3.2.
Paediatric Pharmacy and Formulations An allocation of £77,000 is provided for this service for 2016/17 (2015/16: £100,000).
The service is provided by the University of Liverpool. For 2016/17, funding will be provided to CRN: North West Coast to fund one full-time senior paediatric clinical trials pharmacist who will work with pharmacists based within the LCRNs to provide guidance on the efficient and effective delivery of paediatric trials.
2.3.3.
Chemotherapy and Pharmacy Advisory Service (CPAS) An allocation of £52,844 is provided for this service for 2016/17 (2015/16: no allocation).
CPAS provides a protocol review service to advise chief investigators, clinical trials units and clinical studies groups on the chemotherapy- and pharmacyrelated content of their protocols. Such a review is mandatory for cancer pharmaceutical trials approved by the CRUK CTAAC or the NIHR Health Technology Assessment (HTA) programme. Comprised of a multi-disciplinary national team of pharmacists, research nurses and oncologists, CPAS enables NIHR CRN Portfolio studies to be set up as smoothly and quickly as possible, and improves the quality of care and management of risks in prescribing, preparing and administering chemotherapy. This service has a direct impact on the ability of the NIHR CRN to deliver studies to time and target.
The service is administered within the CRNCC by a Pharmacy Advisor. Funding for CPAS is provided as a top-sliced element for 2016/17.
2.3.4.
NIHR CRN National Specialty Leadership
For 2016/17, the allocation for CRN Specialty National Leadership is £915,060, to fund:
7
NIHR LCRN Funding Allocations 2016/17 Public Version
an allocation of one PA per week for each of 42 Specialty National Leads and Co-Leads
an allocation for administrative support at the rate of 0.1FTE for each Specialty National Lead and Co-Lead (i.e. 42 x 0.1FTE which equals 4.2FTE)
an allocation to meet necessary non-pay costs including costs of National Specialty Group meetings (held three-four times per year for each Specialty)
an allocation to meet institutional overheads at a rate of 8% of pay costs.
Please see Appendix 3 for further details. The funding allocation for each Lead’s Programmed Activity is provided to the LCRN in which that Lead’s employing organisation is located. The arrangements for the provision of administrative support and non-pay cost activities varies according to the CRN Theme Office to which the Specialty relates. Please see Appendix 4 for further details. 2.3.5.
VAT
The funding model makes provision for the VAT cost in cases where the National Specialty Lead currently in post is employed by a HEI. In addition it includes a VAT provision in respect of the Chemotherapy and Pharmacy Advisory Service, which is provided by the University of Leeds.
2.4.
Element B: Activity-based The activity-based element is an allocation of funding based on the volume and complexity of NIHR CRN Portfolio research delivery activity in an LCRN.
The following activity-based components form part of the LCRN funding model for 2016/17:
Recruitment-related component, introduced from 2008/09, based on the number of NHS patients recruited to NIHR CRN Portfolio studies with adjustments for study (and therefore research delivery) complexity;
Project-related component, introduced from 2013/14, based on the number of NIHR CRN Portfolio studies delivered by the LCRN, with adjustments for study complexity.
8
NIHR LCRN Funding Allocations 2016/17 Public Version
2.4.1.
Recruitment-related component Study Complexity Bands As in previous years, the model for 2016/17 allocates funding in proportion to recruitment activity; with study complexity addressed utilising three weighted Study Complexity Bands.
The bands used in 2015/16 remain unchanged for 2016/17:
Band 1 – large (=/> 10,000 participants throughout lifetime of study)
Band 2 – observational
Band 3 – interventional
Study Complexity Weighting For the 2016/17 model, the weighting attached to each study band has been reviewed and revised. The original analysis of a sample of studies to form the model of bands and ratios dated from 2009/10 and 2010/11. During 2014/15 and early 2015/16 the CRNCC undertook an exercise to collate and analyse a new sample of studies. All 15 LCRNs were requested to provide the per patient costs (NHS Support Costs only as specified in Attributing the costs of health and social care Research and Development (AcoRD)) for NIHR CRN Portfolio studies that were led by that LCRN. Data were provided for 544 unique studies in total; 20 studies were categorised as large, 176 as observational, 301 as interventional, and 47 as ‘both’ i.e. with an observational and interventional arm to the study.
At the time of analysis, this sample was equal to 4.8% of the total number of studies on the NIHR CRN Portfolio database (excluding commercial studies and studies withdrawn during set up). The CRN Funding Project Board was content that this was a sufficiently large cohort on which to base the analysis.
On the basis of the analysis undertaken the CRNCC the existing complexity bands set out above have been retained in 2016/17. The complexity ratios have been adjusted for 2016/17 as set out in the table below:
9
NIHR LCRN Funding Allocations 2016/17 Public Version
Complexity Weighting
Rounded Complexity
2015/16
Weighting 2016/17
Band 1 – large
1
1
Band 2 – observational
3
3.5
Band 3 – interventional
14
11
This analysis is used as a benchmark and revisited in two years’ time. The new NIHR CRN Central Portfolio Management System (CPMS) will collect significantly more study-level detail than the current NIHR CRN Portfolio Database, particularly regarding the design of studies. It is anticipated that this data will help to inform future years modelling.
The NHS Support costs reviewed in the analysis demonstrate that the networks are working with greater efficiency despite the increasing complexity of some studies on the NIHR CRN Portfolio e.g. stratified medicine studies.
Rolling average of recruitment When the weighted recruitment figure is calculated for each LCRN in respect of the recruitment-related component, a two-year rolling average is used. So, for the 2015/16 funding allocations, the relevant period was 01/10/2012 to 30/09/2014, and for the 2016/17 funding allocations the relevant period was 01/10/2013 to 30/09/2015.
The arguments in favour of this rolling average are:
It provides stability and smooths out the effect of particular high-recruiting studies.
It provides LCRN allocations based on longer-term trends rather than annual fluctuation.
A higher uplift for one year only is likely to be curtailed by the cap and collar, whereas the two-year rolling average allows an LCRN to maximise the benefit over time.
For an LCRN whose share of weighted recruitment is falling year on year, because the effect of each year’s reduced recruitment takes two years to be fully reflected, it provides the LCRN more time to adjust operationally to a decreasing funding allocation.
10
NIHR LCRN Funding Allocations 2016/17 Public Version
For the 2016/17 model, as in previous years, the two-year rolling average of recruitment data is used. The new Complexity Weighting will be applied to the ‘Year 2’ dataset (i.e. recruitment data for the period 01/10/2014 to 30/09/2015). Data from ‘Year 1’ (01/10/2013 to 30/09/2014) will be weighted using the ‘old’ Complexity Weighting in line with the ratios applied to the LCRN funding model in each year.
Studies that do not report recruitment data A small number of NIHR CRN Portfolio studies collect data from NHS patients using methods that do not meet the current DH definition of recruitment as set out in the Department of Health policy document ‘Eligibility Criteria for NIHR Clinical Research Network Support’ (April 2013). The common feature of these studies is that participants are not knowingly recruited into the study (usually because the studies use anonymised datasets, or because the patient lacks capacity to consent) i.e. informed consent is not required or taken. While these studies are included in the NIHR CRN Portfolio, recruitment data is not uploaded. As in previous years, recruitment data relating to these studies is not available and therefore cannot be included in the LCRN funding model calculations.
Recruitment into multi-centre NIHR BRC/BRU/CLAHRC/ECMC and CRF studies supported by the NIHR CRN As in previous years the CRNCC has considered the data for recruitment of NHS patients into multicentre BRC/BRU/CLAHRC/ECMC and CRF studies supported by the NIHR CRN.
Although some challenges in accurately mapping the recruitment activity for the studies that involved non-CRN NIHR Infrastructure still exist (often due to complex funding arrangements at a local level), as the recruitment attributed to these studies continues to be a relatively small percentage of total recruitment (c.0.5% in 2014/15), the recruitment reported for these studies on the NIHR CRN Portfolio Database is included in the ABF calculations.
Continued improvement in business processes, including the launch of CPMS, will improve data quality and will inform recommendations for 2017/18.
11
NIHR LCRN Funding Allocations 2016/17 Public Version
2.4.2.
Project-related component The project-related component allocates funding in relation to the number of research projects set up and delivered by the LCRN, rather than the number of participants in those studies. This component is intended to recognise activities that are required ‘per project’ rather than ‘per recruit’. Such activities include:
NIHR CSP activities, including both ‘study-wide’ and ‘local’ activities
NIHR CRN Study Support Service activities
The CSP-related allocation is calculated on the number of local reviews and study-wide reviews undertaken by each LCRN from 1 October 2014 to 30 September 2015, weighted according to study complexity (based on IRAS study categories). Study-wide reviews are given an additional weighting. The allocation for NIHR CRN Study Support Service activities is based on the number of study-wide reviews undertaken by each LCRN from 1 October 2014 to 30 September 2015.
Funding for this component remains at the 2015/16 level of £17,060,085.
Using data from the period 01/10/2014 to 30/09/2015, the allocation is made as follows:
57.14% (£9,748,619) for NIHR CSP-related allocation, based on studywide and local reviews
42.86% (£7,311,466) for NIHR CRN Study Support Service-related allocation, based on study wide reviews only.
Please see Appendix 5 for further details.
This represents an interim arrangement. Once HRA Approval and the NIHR CRN Study Support Service are fully implemented the CRNCC will review this funding element to inform 2017/18 funding allocations.
12
NIHR LCRN Funding Allocations 2016/17 Public Version
2.5.
Element C: Performance-based
A performance-based element of NIHR CRN funding was introduced from 2013/14 to recognise and incentivise high performance in study delivery. The total funding allocation for Performance-based funding in 2016/17 is £11m which is comprised of two components, set out below: 2.5.1.
Flow-through Funding The allocation for the ‘flow-through’ funding for 2016/17 is £6m.
The allocation basis is as follows:
a)
£282,442 (4.7% of funding) allocated to sites that achieved first global patient. This allocation is awarded to the NHS provider to reflect retrospective achievement of a first global patient in 2014/15. In the relevant data period (see below) there were 28 first global patients recruited (which were reported to the CRNCC). This allocation has been set at £10,087 per first global patient. This funding will flow through to the relevant NHS provider via the LCRN Host organisation and will reward the achievement of global first patient, given their political importance and impact.
b)
£5,717,558 (95.3% funding) allocated on the basis of time and target performance. The performance metrics used in the 2016/17 funding model are for closed commercial studies which have delivered to time and target using data from High Level Objective (HLO) 2 from the relevant data period (please see below). Each LCRN Partner organisation will receive £3,014 for each study site that recruited to time and target. Funding will flow through to the relevant NHS provider organisations, routed via the LCRN Host organisation. This funding acts as an incentive for the reliable delivery of commercial contract studies by rewarding past performance.
13
NIHR LCRN Funding Allocations 2016/17 Public Version
2.5.2.
CRN Performance Premium
The allocation for the CRN Performance Premium for 2016/17 is £5m. The allocation to an LCRN is based on the number of study sites in that LCRN that have achieved recruitment to time and target in commercial contract research studies.
The CRNCC would like LCRNs to utilise a proportion of this funding element for these specific activities:
i)
Improving feasibility: The CRNCC wants to encourage greater focus in LCRNs on robust feasibility assessment for commercial contract studies. It is intended that once the NIHR CRN Study Support Service is fully implemented and operational this activity will be incorporated within this service.
ii)
Capacity development: The CRNCC wants to encourage LCRNs to identify and develop new ‘green shoots’ sites for commercial contract research over the course of 2016/17 and 2017/18. Typically these are sites with little or no track record of conducting commercial research but which have experience of delivering non-commercial research and in some cases have research delivery teams in place. Funding will be used by the participating organisation to cover costs associated with supporting research-related activities that align with LCRN Industry Team objectives and processes which underpin commercial study delivery.
Data periods used for calculation of the performance-based allocations In previous years, the data period used to calculate allocations for this element was 1 April to 31 March of a previous ‘financial year’; for example, 2015/16 allocations were based on data from the period 1 April 2013 to 31 March 2014.
The CRNCC has changed the data period for the performance-based element so it is aligned with that of the activity-based element, which is from 1 October to 30 September; for example, 2015/16 allocations would be based on data from the period 1 October 2013 to 30 September 2014. This is both for the sake of consistency and in order to ensure that allocations are based on data that is as recent as possible.
14
NIHR LCRN Funding Allocations 2016/17 Public Version
In order to transition without loss of data, the performance-based element is calculated for 2016/17 utilising the data from the ‘financial year’ (1 April 2014 – 31 March 2015) as well as from the second two quarters of the activity-based funding year (i.e. 1 April 2015 – 30 September 2015) i.e. six quarters in total. This will ensure all commercial performance is considered.
Then, from the 2017/18 funding allocation, both activity-based and performancebased allocations will be based on data from the same period, i.e. 1 October 2015 – 30 September 2016). 2.6.
Element D: Population-based The population-based element – also known as the ‘per capita’ element – is an allocation based on an LCRN’s resident population. It ensures that all LCRNs have a minimum provision of NHS Support funding every year, and so supports the principle that NHS patients anywhere in England should be able to access opportunities to take part in clinical research.
In 2015/16, the population-based allocation was £43m (rounded to the nearest £1m) which represented 15% of the total NIHR CRN funding allocation of £284.6m (excluding Network RCF).
The NIHR CRN has retained a population-based allocation for 2016/17 at the 2015/16 level of £43m. Please see Appendix 8.
The calculations use the existing CCG to LCRN mapping which has been agreed with the LCRN Chief Operating Officers.
Updating of resident population estimates LCRN population-based allocations are calculated using Office of National Statistics (ONS) Resident Population Estimates. We used the ONS mid-year 2013 dataset in the calculation of the 2016/17 allocations.
2.7.
Element E: LCRN Host Corporate Support Services LCRN Host organisations are required to provide a range of corporate support facilities and services that facilitate the governance, leadership and management of the LCRN. These services typically include: financial management and
15
NIHR LCRN Funding Allocations 2016/17 Public Version
reporting; human resources (HR); information technology and governance; office space, facilities and equipment; legal and contracting support.
The Corporate Support Services requirements are set out in the NIHR CRN Performance and Operating Framework, which forms part of the DH contract with each LCRN Host organisation.
For 2016/17, the funding allocation for this element remains at the 2015/16 level, which per LCRN is the lower of £400,000 or 2% of total LCRN allocation.
Tables 9a and 9b in Appendix 9 provide further details.
2.8.
Element F: LCRN Leadership and Management The LCRN Leadership and Management element is defined as funding to meet the costs of specified LCRN leadership and senior management posts:
Clinical Director
Chief Operating Officer
Divisional Research Delivery Manager x 6 (one per research delivery division)
Cross-divisional Research Delivery Manager
Industry Operations Manager.
For 2016/17, the model is retained as in 2015/16 i.e. that the leadership and management allocation is based on the core posts as specified in the DH/LCRN contract.
This includes an increase of the allocation per LCRN from £11,735,752 to £12,017,490 (pre Market Forces Factors) in 2016/17. The rationale for the increase is set out below:
there has been a slight increase in the Agenda for Change (AfC) NHS pay rates for some of the managerial bands
employer pension contributions have increased from 14% to 14.3%
16
NIHR LCRN Funding Allocations 2016/17 Public Version
from 5 April 2016 there will be no National Insurance (NI) rebates for contracted out pension schemes, so employer’s NI will increase which we have factored into the 2016/17 model.
The CRNCC has calculated indicative costs for these posts based on the 2015/16 AfC pay rates for the expected NHS band for each post (taken at the top of the band). An additional 8% for direct non-staff costs (travel, equipment etc.) has also been included in the calculations.
See Appendix 10 for further details.
2.9.
Adjustments
2.9.1.
NHS Market Forces Factor Since 2013/14, NHS Market Forces Factor (MFF) weightings have been applied to all CLRN/LCRN funding elements in order to allow for regional differences in NHS costs. This continues to be well received by NHS organisations and this treatment continues for 2016/17.
In 2015/16, the MFF index for each LCRN was determined by taking the median MFF index of the LCRN Partner organisations (including the Host Trust).
For the 2016/17 funding model, the MFF index for each LCRN uses the weighted average MFF index for the LCRN Partner organisations including the Host Trust, where the Partner organisation has been assigned a MFF index, therefore only NHS Trusts are included.
For each NHS Trust that is an LCRN Partner organisation, the MFF index is weighted according to their 2014/15 full year core spend. The calculation is derived by taking the MFF index for each relevant Partner organisation and then weighting this according to their individual spend as a proportion of the total spend of the NHS Trusts within that LCRN.
The MFF index for the LCRN is then calculated as the resulting weighted average.
17
NIHR LCRN Funding Allocations 2016/17 Public Version
This method takes into consideration the amount of funding passing to every Partner organisation, and allows the MFF to reflect more accurately the effect of regional differences in NHS costs on an LCRN. The previous method did not reflect either the relative sizes of the Partner organisations in their contribution to the LCRN MFF, or the actual values of the Partner organisations MFF indices on either side of the median.
Please see Appendix 11 for details of the MFF index for each LCRN.
The MFF index has been applied to every component of LCRN allocations, with the exception of top-sliced element and the performance-based element (both the flow-through and the Performance Premium components) 2.9.2.
Cap and Collar The LCRN funding model applies a percentage ‘cap and collar’ to LCRN allocations in order to avoid major fluctuations in funding year-on-year, which provides stability in the NIHR infrastructure and allow LCRNs to plan more effectively.
For 2014/15 and 2015/16 the CRNCC applied a cap and collar of +5% / -5%.
The CRNCC considered amending the cap and collar for 2016/17 and in particular evaluated the ‘pros and cons’ of widening the cap and collar to +/7.5% or indeed +/-10%. The CRNCC consulted widely with LCRNs and CRN Specialties on this issue and the very strong view from the CRN is that a change at this stage of LCRN development would create unnecessary uncertainty and instability, with potentially adverse consequences for the universal provision of NHS Support.
The cap and collar is therefore retained at +/-5%.
2.9.3.
Data Mapping As in previous years, the CRNCC has undertaken an exercise in 2015/16 to ensure all NHS Trusts, GP Practices and other NHS providers, and also Clinical Commissioning Groups, are correctly mapped to LCRNs. Data showing all studies open in financial year 2015/16 were supplied to the LCRNs. Issues
18
NIHR LCRN Funding Allocations 2016/17 Public Version
arising from this exercise were addressed by the CRNCC in collaboration with the LCRNs. The resultant changes, which inform the 2016/17 funding allocations, are noted in Appendix 12.
19
NIHR LCRN Funding Allocations 2016/17 Public Version
3. TABLES
Table 1. Comparison of LCRN funding allocations 2015/16 and 2016/17
Table 2. Recruitment Activity Data used for the 2016/17 LCRN allocations
Table 3. 2016/17 LCRN funding – Income elements
Table 4. 2016/17 LCRN funding - Expenditure elements
Table 5. top-sliced elements, 2015/16 and 2016/17
Table 6a. LCRN funding allocations 2016/17 (not including flow-through and top-sliced elements)
Table 6b. LCRN funding allocations 2016/17 (including flow-through and top-sliced elements)
20
NIHR LCRN Funding Allocations 2016/17 Public Version
Table 1. Comparison of LCRN funding allocations 2015/16 and 2016/17
LCRN
2
2016/17 2 Allocation
Difference (£)
Difference (%)
East Midlands
£20,636,833
£20,761,380
£124,547
0.6%
Eastern
£19,720,577
£18,815,152
(£905,425)
(4.6%)
Greater Manchester
£17,270,846
£17,690,860
£420,014
2.4%
Kent, Surrey and Sussex
£15,292,789
£14,528,150
(£764,639)
(5.0%)
North East and North Cumbria
£19,541,964
£18,658,443
(£883,521)
(4.5%)
North Thames
£30,905,343
£31,717,863
£812,520
2.6%
North West Coast
£16,034,608
£15,232,878
(£801,730)
(5.0%)
North West London
£12,796,628
£13,436,459
£639,831
5.0%
South London
£22,717,840
£23,853,732
£1,135,892
5.0%
South West Peninsula
£11,335,160
£10,768,402
(£566,758)
(5.0%)
Thames Valley and South Midlands
£13,690,247
£13,339,151
(£351,096)
(2.6%)
Wessex
£15,536,341
£15,684,784
£148,443
1.0%
West Midlands
£30,030,770
£28,529,232
(£1,501,538)
(5.0%)
West of England
£12,786,308
£12,544,172
(£242,136)
(1.9%)
Yorkshire and Humberside
£28,419,512
£26,998,536
(£1,420,976)
(5.0%)
£286,715,766
£282,559,194
(£4,156,572)
(1.4%)
Total 1
2015/16 1 Allocation
Total of Core Funding and RCF, excluding flow-through and top-sliced elements, post cap and post MFF Excluding flow-through and top-sliced elements, post cap and post MFF
21
NIHR LCRN Funding Allocations 2016/17 Public Version
Table 2. Recruitment activity data used for the 2016/17 LCRN allocations Weighted Recruitment LCRN
2 year average
Weighted Recruitment 2 year average
% Change Up / (Down)
% Change in Allocation 2015/16 to 2016/17 1
(2012/13 to 2013/14) 218,557
(2013/14 to 2014/15) 216,850
(0.8%)
0.6%
Eastern
215,173
187,251
(13.0%)
(4.6%)
Greater Manchester
174,300
179,041
2.7%
2.4%
Kent, Surrey and Sussex
138,333
104,809
(24.2%)
(5.0%)
A
North East and North Cumbria
264,669
204,499
(22.7%)
(4.5%)
B
North Thames
295,283
272,554
(7.7%)
North West Coast
163,227
133,889
(18.0%)
(5.0%)
A
North West London
111,357
127,760
14.7%
5.0%
C
South London
229,017
240,656
5.1%
5.0%
C
South West Peninsula
109,915
86,346
(21.4%)
(5.0%)
A
Thames Valley and South Midlands
141,583
125,872
(11.1%)
(2.6%)
Wessex
163,648
152,656
(6.7%)
1.0%
West Midlands
355,082
277,160
(21.9%)
West of England
131,857
123,154
(6.6%)
Yorkshire and Humberside
335,246
272,473
(18.7%)
3,047,244
2,704,969
(11.2%)
East Midlands
Total
2.6%
(5.0%)
A
(1.9%) (5.0%)
1
Post MFF and Cap and Collar, excluding top-sliced and flow-through elements
A
Reduction in funding is limited by collar
B
In 2015/16 the upper cap of 5% restricted funding, meaning the allocation was £2m lower than it would have been without the cap. Therefore the large %
A
reduction in weighted recruitment in the 2016/17 model translates only into a large reduction in allocation compared to 2015/16 pre-cap, not 2015/16 post cap.
22
NIHR LCRN Funding Allocations 2016/17 Public Version C
Increase in funding is limited by cap
Note: 2013/14 Interventional studies were weighted by a factor of 14, 2014/15 Interventional studies were weighted by a factor of 11.
Table 3. 2016/17 LCRN funding – Income elements Income Element National (top-sliced)
2016/17 Allocation
% of Total
£2,040,806
0.7%
£222,541,704
76.6%
Performance-based
£11,000,000
3.8%
Population-based
£43,000,000
14.8%
LCRN Leadership and Management
£12,017,490
4.1%
£290,600,000
100.0%
Activity-based
Total Note: All elements in Table 3 are pre-MFF and Pre-Cap and Collar.
Table 4. 2016/17 LCRN funding - Expenditure elements Expenditure Element National (top-sliced)
2016/17 Allocation
% of Total
£2,040,806
0.7%
£12,017,490
4.1%
£5,105,698
1.8%
NHS Support
£271,436,006
93.4%
Total
£290,600,000
100.0%
LCRN Leadership and Management LCRN Corporate Support Services
23
NIHR LCRN Funding Allocations 2016/17 Public Version
Table 5. Top-sliced elements, 2015/16 and 2016/17 Top-sliced component
2015/16 Allocation
2016/17 Allocation
Change Up / (Down)
RTTQA
£927,512
£995,902
£68,390
Paediatric Pharmacy and Formulations
£100,000
£77,000
(£23,000)
Specialty National Leads
£666,722
£915,060
£248,338
£0
£52,844
£52,844
£1,694,234
£2,040,806
£346,572
£282,905,766
£288,559,194
£5,653,428
£9,900,000
£0
(£9,900,000)
£294,500,000
£290,600,000
(£3,900,000)
Chemotherapy and Pharmacy Advisory Service Sub Total Remaining Core Allocation RCF Allocation Total
24
NIHR LCRN Funding Allocations 2016/17 Public Version
Table 6a: LCRN funding allocations 2016/17 (not including flow-through and top-sliced elements)
Activity-based allocations
LCRN
Leadership and Management
Populationbased
Performance Premium
Projectbased
Recruitmentbased
2016/17 Allocation1
Effect of Market Forces Factor2
Effect of +/5% Cap and Collar
2016/17 Allocation3
East Midlands
£801,166
£3,541,278
£361,094
£851,946
£16,472,900
£22,028,384
(£1,155,120)
(£111,884)
£20,761,380
Eastern
£801,166
£2,993,185
£353,189
£977,412
£14,224,389
£19,349,341
(£432,794)
(£101,395)
£18,815,152
Greater Manchester
£801,166
£2,349,754
£453,348
£1,282,758
£13,600,759
£18,487,785
(£701,589)
(£95,336)
£17,690,860
Kent, Surrey and Sussex
£801,166
£3,589,566
£239,853
£633,689
£7,961,744
£13,226,018
£230,085
£1,072,047
£14,528,150
North East and North Cumbria
£801,166
£2,317,411
£313,653
£971,334
£15,534,663
£19,938,227
(£1,179,233)
(£100,551)
£18,658,443
North Thames
£801,166
£4,363,011
£527,148
£2,287,233
£20,704,408
£28,682,966
£3,205,825
(£170,928)
£31,717,863
North West Coast
£801,166
£3,118,371
£250,396
£794,546
£10,170,829
£15,135,308
(£791,905)
£889,475
£15,232,878
North West London
£801,166
£1,607,307
£213,495
£1,199,206
£9,705,205
£13,526,379
£1,694,911
(£1,784,831)
£13,436,459
South London
£801,166
£2,521,002
£384,818
£2,004,739
£18,281,311
£23,993,036
£3,111,448
(£3,250,752)
£23,853,732
South West Peninsula
£801,166
£1,780,943
£292,568
£506,813
£6,559,249
£9,940,739
(£708,976)
£1,536,639
£10,768,402
Thames Valley and South Midlands
£801,166
£1,853,874
£121,244
£905,552
£9,561,784
£13,243,620
£167,416
(£71,885)
£13,339,151
Wessex
£801,166
£2,321,368
£295,203
£960,439
£11,596,455
£15,974,631
(£205,321)
(£84,526)
£15,684,784
West Midlands
£801,166
£4,530,009
£469,162
£1,403,714
£21,054,338
£28,258,389
(£1,458,389)
£1,729,232
£28,529,232
West of England
£801,166
£1,766,051
£234,581
£663,013
£9,355,293
£12,820,104
(£208,331)
(£67,601)
£12,544,172
Yorkshire and Humberside
£801,166
£4,346,870
£490,248
£1,617,691
£20,698,292
£27,954,267
(£1,568,027)
£612,296
£26,998,536
£12,017,490
£43,000,000
£5,000,000
£17,060,085
£205,481,619
£282,559,194
£0
£0
£282,559,194
4.1%
14.8%
1.7%
5.9%
70.7%
0.0%
0.0%
Total % of Total Allocation 1
Excluding flow-through and top-sliced elements, pre MFF, pre Cap and Collar MFF applies to all funding elements excluding flow-through and top-sliced elements 3 Excluding flow-through and top-sliced elements, post MFF, post Cap and Collar 2
25
NIHR LCRN Funding Allocations 2016/17 Public Version
Table 6b: LCRN funding allocations 2016/17 (showing flow-through and top-sliced allocations) Top-sliced Allocations
LCRN
2016/17 Allocation Adjusted1
Performance flow-through
Specialty National Leadership
RTTQA
Paediatric Pharmacy and Formulations Funding
Chemotherapy and Pharmacy Advisory Service
2016/17 Allocation
Corporate Support Services2
TOTAL
East Midlands
£20,761,380
£443,185
£0
£39,414
£0
£0
£21,243,979
£400,000
Eastern
£18,815,152
£413,963
£995,902
£65,045
£0
£0
£20,290,062
£400,000
Greater Manchester
£17,690,860
£538,582
£0
£89,945
£0
£0
£18,319,387
£366,388
Kent, Surrey and Sussex
£14,528,150
£274,274
£0
£0
£0
£0
£14,802,424
£296,048
North East and North Cumbria
£18,658,443
£378,840
£0
£90,570
£0
£0
£19,127,853
£382,557
North Thames
£31,717,863
£633,061
£0
£77,090
£0
£0
£32,428,014
£400,000 £313,930
North West Coast
£15,232,878
£326,678
£0
£59,928
£77,000
£0
£15,696,484
North West London
£13,436,459
£264,308
£0
£49,015
£0
£0
£13,749,782
£274,996
South London
£23,853,732
£450,131
£0
£48,900
£0
£0
£24,352,763
£400,000
South West Peninsula
£10,768,402
£344,641
£0
£58,470
£0
£0
£11,171,513
£223,430
Thames Valley and South Midlands
£13,339,151
£158,818
£0
£42,414
£0
£0
£13,540,383
£270,808
Wessex
£15,684,784
£347,655
£0
£32,200
£0
£0
£16,064,639
£321,293
West Midlands
£28,529,232
£546,579
£0
£38,690
£0
£0
£29,114,501
£400,000
West of England
£12,544,172
£268,246
£0
£0
£0
£0
£12,812,418
£256,248
Yorkshire and Humberside LCRN Total % of Total Allocation
£26,998,536
£611,039
£0
£223,379
£0
£52,844
£27,885,798
£400,000
£282,559,194
£6,000,000
£995,902
£915,060
£77,000
£52,844
£290,600,000
£5,105,698
2.1%
0.3%
0.3%
0.0%
0.0%
100.0%
1.8%
1
Excluding flow-through and top-sliced elements, post MFF, post Cap and Collar The Corporate Support Services element of £5,105,698 is already included in the total 2016/17 allocation i.e. the 1.8% funding allocation for Corporate Support Services are included within the 100%. 2
26
NIHR LCRN Funding Allocations 2016/17 Public Version
4. APPENDICES Appendix 1: Membership of NIHR CRN Funding Project Board & NIHR CRN Funding and Financial Management Steering Group 1a. Membership of the NIHR CRN Funding Project Board Chair John Sitzia Chief Operating Officer, NIHR CRNCC Members Amber O’Malley
Head of Performance Management
CRNCC
Sally Johnson
LCRN Funding and Contracts Manager
CRNCC
Tara Bhogal
Head of Finance
CRNCC
Ruth Jessop
LCRN Finance Manager
CRNCC
Helen Jones
Assistant LCRN Finance Manager
CRNCC
Jonathan Gower
Assistant Theme Lead, Theme F
CRNCC
Nadine Boczkowski
Head of Business Intelligence
CRNCC
Lydia Christopher
Head of Industry
CRNCC
Helen Quinn
Chief Operating Officer
CRN: South West Peninsula
Rebecca MacKay
Chief Operating Officer
CRN: CRN Wessex
John Sheedy
Head of Finance and Information
CRN: North Thames
Helen Macdonald
Research Delivery Manager
CRN: Eastern
Jeremy Brinley-Codd
Assistant Director of Finance – Financial Developments &
Guys & St Thomas’ NHS Foundation Trust
Costings
27
NIHR LCRN Funding Allocations 2016/17 Public Version
1b. Membership of the NIHR CRN Funding and Financial Management Steering Group Chair Angela Byram Faculty Finance Director (Faculty of Medicine & Health) University of Leeds Members John Sitzia
Chief Operating Officer
CRNCC
Amber O’Malley
Head of Performance Management
CRNCC
Tara Bhogal
Head of Finance
CRNCC
Ruth Jessop
LCRN Finance Manager
CRNCC
Sally Johnson
LCRN Funding and Contracts Manager
CRNCC
Helen Jones
Assistant LCRN Finance Manager
CRNCC
Laura Bousfield
Study Start Up Manager
CRNCC
Joanne Ashcroft
Assistant Theme Lead, Theme C
CRNCC
Mahesh Kataria
Assistant LCRN Finance Manager
CRNCC
Val Woods
Chief Operating Officer
CRN: Thames Valley and South Midlands
Rebecca McKay
Chief Operating Officer
CRN: Wessex
Kirsty Cepek
Assistant Director of Finance, University Hospitals Bristol NHS
CRN: West of England
Foundation Trust Chris Taylor
Finance Manager & EtL Facilitator
CRN: North West Coast
John Sheedy
Head of Finance and Information
CRN: North Thames
Gillian Chater
Assistant Finance Director R&D, Newcastle Upon Tyne Hospitals NHS
CRN: North East and North Cumbria
Foundation Trust Martin Maynes
Research & Development Finance Lead, University Hospitals of Leicester
CRN: East Midlands
NHS Trust Stephen Devereux
Clinical Director
CRN: South London
Jeremy Brinley-Codd
Assistant Director of Finance – Financial Developments & Costings
Guys & St Thomas’ NHS Foundation Trust
28
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 2: Past and Future Funding for the National RTTQA Group RTTQA STAFFING
COSTS
Annual Allocation
Phase 3 and larger phase 2 trials Early phase trials Clinical Fellow Advanced technique QA Paediatric trial support Systems analyst Proton beam irradiation Adaptive RT (include MR-Linac) Molecular radiotherapy
Year 4 2013/14 12 2 1 1
Year 5 2014/15 12 2 1 1
Year 6 2015/16 12 [1] 2 [1] 1 1 0.5
Year 7 2016/17 12 2 1 1 0.5 0.5
Year 8 2017/18
0.5 0.25
12 2 1 1 0.5 0.5 0.5 0.5 0.5
Year 9 2018/19 12 2 1 1 0.5 0.5 1 0.5 0.5
Phase 3 and larger phase 2 trials [2] Early phase trials [2] Clinical Fellow [3] Advanced technique QA [4] Paediatric trial support [2] Systems analyst [2] Proton beam irradiation [2] Adaptive RT (MR-Linac) [2] Molecular radiotherapy [2] Core funding costs [5]
£589,272
£589,272
£608,544
£608,544
£608,544
£608,544
£98,212 £60,040 £71,920
£98,212 £60,040 £71,920
£101,424 £60,040 £71,920 £25,356
£101,424 £60,040 £71,920 £25,356 £25,356
£60,000
£60,000
£60,228
£25,356 £12,678 £65,228 [6]
£101,424 £60,040 £71,920 £25,356 £25,356 £25,356 £25,356 £25,356 £65,228 [6]
£101,424 £60,040 £71,920 £25,356 £25,356 £50,712 £25,356 £25,356 £65,228 [6]
Staff costs
£819,444
£819,444
£867,284
£930,674
£968,708
£994,064
Core costs
£60,000 £879,444
£60,000 £879,444
£60,228 £927,512
£65,228 £995,902
£65,228 £1,033,936
£65,228 £1,059,292
[1] Current staff breakdown for trials: Phase 3 and larger phase 2 trials: 7.2WTE physicists and 3.8WTE radiographers
29
NIHR LCRN Funding Allocations 2016/17 Public Version
[2] [3] [4] [5] [6]
Early phase trials: 1.2WTE physicists and 0.4WTE radiographers (Staff bandings range from band 6 to band 9) Based on mid band 7, 2014 salary scale -includes on costs (physicist and radiographer posts) Based salary band clinical 8 includes on costs (clinical fellow) Based on mid band 8b, 2014 salary scale -includes on costs (physicist post) General running costs to include essential RTQA equipment, computer hardware and software purchase plus ongoing support, office and stationary costs, staff travel and meeting costs. Additional 5K per year to establish and run working groups associated with areas of future development
30
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 3: Funding model for NIHR CRN National Specialty Leads / Co-Leads
Main Specialty
National Specialty Lead / Co-Leads PAs
National Specialty Lead / Co-Lead pay cost
Admin support WTE
Admin Support pay cost
Overheads (8% of pay costs)
Non pay
VAT
1
TOTAL
Ageing
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Anaesthesia Peri-op Medicine & Pain Management
1
£12,500
0.1
£3,097
£1,248
£2,500
£0
£19,345
Cancer
6
£75,000
0.6
£18,582
£7,488
£15,000
£12,414
£128,484
Cardiovascular Disease
3
£37,500
0.3
£9,291
£3,744
£7,500
£0
£58,035
Children
2
£25,000
0.2
£6,194
£2,496
£5,000
£0
£38,690
Critical Care
1
£12,500
0.1
£3,097
£1,248
£2,500
£0
£19,345
DeNDRoN
2
£25,000
0.2
£6,194
£2,496
£5,000
£7,738
£46,428
Dermatology
1
£12,500
0.1
£3,097
£1,248
£2,500
£0
£19,345
Diabetes
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Ear Nose and Throat
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Gastroenterology
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Genetics
1
£12,500
0.1
£3,097
£1,248
£2,500
£1,169
£20,514
Haematology
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Health Services & Delivery Research
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,200
£22,545
Hepatology
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Infectious Diseases and Microbiology
1
£12,500
0.1
£3,097
£1,248
£2,500
£669
£20,014
Injuries and Emergencies
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,200
£22,545
Mental Health
2
£25,000
0.2
£6,194
£2,496
£5,000
£7,738
£46,428
Metabolic and Endocrine Disorders
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Musculoskeletal Disorders
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
31
NIHR LCRN Funding Allocations 2016/17 Public Version
National Specialty Lead / Co-Leads PAs
Main Specialty
National Specialty Lead / Co-Lead pay cost
Admin support WTE
Admin Support pay cost
Overheads (8% of pay costs)
Non pay
VAT
1
TOTAL
Neurological disorders
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Ophthalmology
1
£12,500
0.1
£3,097
£1,248
£2,500
£0
£19,345
Oral & dental health
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Primary Care
2
£25,000
0.2
£6,194
£2,496
£5,000
£7,738
£46,428
Public Health
1
£12,500
0.1
£3,097
£1,248
£2,500
£669
£20,014
Renal disorders
1
£12,500
0.1
£3,097
£1,248
£2,500
£0
£19,345
Reproductive Health and Childbirth
2
£25,000
0.2
£6,194
£2,496
£5,000
£7,738
£46,428
Respiratory disorders
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Stroke
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
Surgery
1
£12,500
0.1
£3,097
£1,248
£2,500
£3,869
£23,214
TOTAL
42
£525,000
4.2
£130,074
£52,416
£105,000
£102,570
£915,060
1
payable where funding is passed to a HEI
Salary (2015/16 Admin Support Band 5, point 20 0.1 WTE
payscales) £25,047
Employers NI Pension (14.3%) £3,582
(Calculated) £2,337
Total £30,966 £3,097
32
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 4: NIHR CRN National Specialty Leads funding 2015/16 and 2016/17 Theme
2015/16 funding arrangements (Q2-Q4)
2016/17 funding arrangements
A
National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based.
Same arrangements in 2016-17 as in 2015-16.
0.1 FTE Admin Support based at same location as National Specialty Lead. Non-pay costs to be routed to LCRNs where National Specialty Leads are based. B
C
National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based.
National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based.
0.1 FTE Admin Support based at same location as National Specialty Lead.
0.1 FTE Admin Support routed to Theme Office.
Non-pay costs to be routed to LCRNs where National Specialty Leads are based. National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based.
Non-pay costs to be routed to LCRNs where National Specialty Leads are based. Same arrangements in 2016-17 as in 2015-16.
Amalgamation of the 0.1FTEs associated with their National Specialty Leads into posts which will be based in the Specialty Hub Cluster (Theme) Offices. 0.45 WTE admin located with Professor Stephen Smye (National Theme Lead) at Leeds Teaching Hospitals NHS Trust to cover the (A) cluster. 50% of Admin Support to be routed to CRN: Yorkshire & Humber (for Leeds Teaching Hospitals NHS Trust). 0.45 WTE admin located with Dr Philip Evans (National Theme Lead) at the University of Exeter to cover the (B) cluster. 50% of Admin Support to be routed to CRN: South West Peninsula (for University of Exeter). Non-pay costs to be routed to LCRNs where National Specialty Leads are based.
33
NIHR LCRN Funding Allocations 2016/17 Public Version
Theme
2015/16 funding arrangements (Q2-Q4)
2016/17 funding arrangements
D
National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based.
Same arrangements in 2016-17 as in 2015-16.
0.1 FTE Admin Support based at same location as National Specialty Lead.
E
Non-pay costs to be routed to LCRNs where National Specialty Leads are based. National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based. 5 x 0.1 FTE Admin Support posts combined to enable appointment of two 0.8 FTE substantive posts in the Theme Office.
F
Non-pay costs to be routed to LCRNs where National Specialty Leads are based. National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based. Amalgamation of the 0.1FTEs associated with their National Specialty Leads into posts which will be based in the Theme Offices.
National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based. All admin support and non-pay costs to be routed to the Theme Office.
National Specialty Lead funding for each Specialty to be routed to LCRNs where National Specialty Leads are based. All admin support and non-pay costs to be routed to the Theme Office.
One 0.8 FTE post in the Theme Office based at the University of Leeds. All Admin Support and non-pay costs to be routed to CRN: Yorkshire & Humber.
34
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 5: 2016/17 funding allocations for project-based element The project-based services funding is based on the number of completed study wide and local reviews undertaken by each LCRN, weighted according to IRAS category. The table shows the % of the total study wide and local reviews delivered by each LCRN for CSP-related activities and the % of the total study reviews delivered by each LCRN for the Study Support Services-related activities. The table also shows the funding allocations for each activity and overall total.
LCRN East Midlands
CSP-related Allocation
Study Support Service Allocation
% of Total Allocation 5.4% £530,778
% of Total Allocation 4.4% £321,168
Total £851,946
Eastern
5.8%
£569,017
5.6%
£408,395
£977,412
Greater Manchester
7.5%
£731,623
7.5%
£551,135
£1,282,758
Kent, Surrey and Sussex
4.3%
£419,579
2.9%
£214,110
£633,689
North East and North Cumbria
6.0%
£586,729
5.3%
£384,605
£971,334
14.9% £1,090,376
£2,287,233
North Thames
12.3% £1,196,857
North West Coast
5.2%
£509,066
3.9%
£285,480
£794,546
North West London
6.2%
£604,456
8.1%
£594,750
£1,199,206
South London
9.9%
£969,873
14.2% £1,034,866
£2,004,739
South West Peninsula
4.0%
£391,828
1.6%
£114,985
£506,813
Thames Valley and South Midlands
4.5%
£441,647
6.3%
£463,905
£905,552
Wessex
5.9%
£579,799
5.2%
£380,640
£960,439
West Midlands
9.2%
£900,159
6.9%
£503,555
£1,403,714
West of England
3.9%
£377,533
3.9%
£285,480
£663,013
Yorkshire and Humberside
9.6%
£939,675
9.3%
£678,016
£1,617,691
100.0% £7,311,466
£17,060,085
Total
100.0% £9,748,619
35
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 6: Total Number of Sites Achieving Recruitment to Time and Target for Commercial Studies 2015/16
2016/17
o
LCRN
N of sites achieved recruitment target within time (4 quarters)
o
% of Total
2015/16 Performance Premium
N of sites achieved recruitment target within time (6 quarters)
% of Total
2016/17 Performance Premium
East Midlands
69
8.0%
£400,231
137
7.2%
£361,094
Eastern
55
6.4%
£319,026
134
7.1%
£353,189
Greater Manchester
93
10.8%
£539,443
172
9.1%
£453,348
Kent, Surrey and Sussex
37
4.3%
£214,617
91
4.8%
£239,853
North East and North Cumbria
53
6.1%
£307,425
119
6.3%
£313,653
101
11.7%
£585,847
200
10.5%
£527,148
North West Coast
54
6.3%
£313,225
95
5.0%
£250,396
North West London
37
4.3%
£214,617
81
4.3%
£213,495
South London
67
7.8%
£388,631
146
7.7%
£384,818
South West Peninsula
38
4.4%
£220,418
111
5.9%
£292,568
Thames Valley and South Midlands
21
2.4%
£121,810
46
2.4%
£121,244
Wessex
55
6.4%
£319,026
112
5.9%
£295,203
West Midlands
69
8.0%
£400,232
178
9.4%
£469,162
West of England
37
4.3%
£214,617
89
4.7%
£234,581
Yorkshire and Humberside
76
8.8%
£440,835
186
9.8%
£490,248
862
100.0%
£5,000,000
1897
100.0%
£5,000,000
North Thames
Total
36
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 7: Performance-based funding allocations 2016/17 Flow-through component LCRN
Global 1 Firsts
££ Global 2 Firsts
Sites
££ 4 Sites
3
Flowthrough TOTAL
Performance Premium
TOTAL
East Midlands
3
£30,267
137
£412,918
£443,185
£361,094
£804,279
Eastern
1
£10,087
134
£403,876
£413,963
£353,189
£767,152
Greater Manchester
2
£20,174
172
£518,408
£538,582
£453,348
£991,930
Kent, Surrey and Sussex
0
£0
91
£274,274
£274,274
£239,853
£514,127
North East and North Cumbria
2
£20,174
119
£358,666
£378,840
£313,653
£692,493
North Thames
3
£30,261
200
£602,800
£633,061
£527,148
£1,160,209
North West Coast
4
£40,348
95
£286,330
£326,678
£250,396
£577,074
North West London
2
£20,174
81
£244,134
£264,308
£213,495
£477,803
South London
1
£10,087
146
£440,044
£450,131
£384,818
£834,949
South West Peninsula
1
£10,087
111
£334,554
£344,641
£292,568
£637,209
Thames Valley and South Midlands
2
£20,174
46
£138,644
£158,818
£121,244
£280,062
Wessex
1
£10,087
112
£337,568
£347,655
£295,203
£642,858
West Midlands
1
£10,087
178
£536,492
£546,579
£469,162
£1,015,741
West of England
0
£0
89
£268,246
£268,246
£234,581
£502,827
Yorkshire and Humberside
5
£50,435
186
£560,604
£611,039
£490,248
£1,101,287
28
£282,442
1,897
£5,717,558
£6,000,000
£5,000,000
£11,000,000
52.0%
54.5%
45.5%
100.0%
Total % of Total performance-based
2.6%
1
Number of Global First Patient Recruited in the period 1 April 2014 to 30 September 2015 Allocation based on the number of ‘Global Firsts’. This funding is intended to flow through to Investigator / study team 3 Number of LCRN study-sites that delivered to time and target in the period 1 April 2014 to 30 September 2015 4 Intended to flow through participating organisation for onward distribution Note: Global First funding is £10,087 per event. Site recruiting to time and target flow-through is £3,014 per event 2
37
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 8: Calculation of population-based funding allocations
LCRN
2
Adjustments
2
Adjusted LCRN population
% of total
2016/17 Allocation
East Midlands
4,436,135
4,436,135
8.2%
£3,541,278
Eastern
3,749,543
3,749,543
7.0%
£2,993,185
Greater Manchester
2,943,521
2,943,521
5.5%
£2,349,754
Kent, Surrey and Sussex
4,496,626
4,496,626
8.3%
£3,589,566
North East and North Cumbria
3,114,619
2,903,006
5.4%
£2,317,411
North Thames
5,465,515
5,465,515
10.1%
£4,363,011
North West Coast
3,694,749
3,906,362
7.3%
£3,118,371
North West London
2,013,463
2,013,463
3.7%
£1,607,307
South London
3,158,043
3,158,043
5.9%
£2,521,002
South West Peninsula
2,230,976
2,230,976
4.1%
£1,780,943
Thames Valley and South Midlands
2,322,336
2,322,336
4.3%
£1,853,874
Wessex
2,722,840
2,907,962
5.4%
£2,321,368
West Midlands
5,674,712
5,674,712
10.5%
£4,530,009
West of England
2,397,443
2,212,321
4.1%
£1,766,051
Yorkshire and Humber
5,445,296
5,445,296
10.1%
£4,346,870
53,865,817
100.0%
£43,000,000
Total 1
LCRN 1 Population
-211,613 211,613
185,122 -185,122
53,865,817
0
Mid-2013 ONS data by mapped to CCGs Adjustments agreed between LCRNs to reflect anomalies in CCG mappings
38
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 9: Corporate Support Services funding allocations Table 9a: Calculation of Corporate Support Services funding allocations
Salary Band (midService area
Role
Finance
Assistant Finance Director
Finance
point)
WTE
with on-
8% direct
costs
non-staff
Total
8D
0.2
£19,000
£1,520
£20,520
Management Accountant
7
1
£44,000
£3,520
£47,520
Finance
Finance Officer
5
1
£30,000
£2,400
£32,400
HR
HR Manager
8A
0.5
£27,000
£2,160
£29,160
Estates and Facilities including IS
£61,960
Governance / Contract administration
£50,000
Total
£241,560
39
NIHR LCRN Funding Allocations 2016/17 Public Version
Table 9b: LCRN Host Corporate Support Services funding allocations for each LCRN
Total Allocation 2016/17 £21,243,979
Corporate Support Services (Within Total Allocation 2016/17) £400,000
Corporate Support Services % of Total 1.9%
Eastern
£20,290,062
£400,000
2.0%
Greater Manchester
£18,319,387
£366,388
2.0%
Kent, Surrey and Sussex
£14,802,424
£296,048
2.0%
North East and North Cumbria
£19,127,853
£382,557
2.0%
North Thames
£32,428,014
£400,000
1.2%
North West Coast
£15,696,484
£313,930
2.0%
North West London
£13,749,782
£274,996
2.0%
South London
£24,352,763
£400,000
1.6%
South West Peninsula
£11,171,513
£223,430
2.0%
Thames Valley and South Midlands
£13,540,383
£270,808
2.0%
Wessex
£16,064,639
£321,293
2.0%
West Midlands
£29,114,501
£400,000
1.4%
West of England
£12,812,418
£256,248
2.0%
Yorkshire and Humber
£27,885,798
£400,000
1.4%
£290,600,000
£5,105,698
1.8%
Local Clinical Research Network East Midlands
Total
40
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 10: LCRN Leadership and Management funding allocations for each LCRN
Role LCRN Clinical Director LCRN Chief Operating Officer LCRN Research Delivery Divisional Managers × 7 (including Cross-Divisional Manager) LCRN Industry Operations Manager Total
Salary + pension + NI £62,500
Indirect non-staff £0
8% direct non-staff £5,000
Total (per LCRN) £67,500
Total (× 15 LCRNs) £1,012,500
% of total £294.5m allocation 0.34%
Band Consultant
WTE / PA 5 PA
8d
1.0 WTE
£103,433
£0
£8,275
£111,708
£1,675,620
0.57%
8b
7.0 WTE
£503,901
£0
£40,312
£544,213
£8,163,195
2.77%
8b
1.0 WTE
£71,986 £741,820
£0 £0
£5,759 £59,346
£77,745 £801,166
£1,166,175 £12,017,490
0.40% 4.08%
41
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 11: 2016/17 MFF index per LCRN
MFF index 2015/16 (median method) 3.60%
MFF index 2016/17 (weighted average method) 3.90%
Eastern
7.73%
7.20%
Greater Manchester
5.13%
5.49%
10.16%
11.56%
2.86%
3.17%
19.88%
21.91%
3.99%
3.91%
North West London
20.14%
23.39%
South London
20.45%
23.87%
1.94%
1.83%
14.42%
11.04%
Wessex
7.90%
8.24%
West Midlands
3.94%
3.99%
West of England
7.66%
7.87%
Yorkshire and Humber
3.40%
3.50%
Local Clinical Research Network East Midlands
Kent, Surrey and Sussex North East and North Cumbria North Thames North West Coast
South West Peninsula Thames Valley and South Midlands
42
NIHR LCRN Funding Allocations 2016/17 Public Version
Appendix 12: Trust to LCRN mapping changes and resulting funding change
Average Weighted Recruitment (2013/14 & 2014/15) Sites affected 22 GP practices within Wiltshire CCG 34 GP practices within Cumbria CCG Heatherwood Hospital, Wexham Park Hospital
Former LCRN West of England
New LCRN Wessex
North East and North Cumbria
North West Coast
Thames Valley and South Midlands
Kent, Surrey and Sussex
Effect on ABF funding allocation (pre MFF and cap and collar) - £
Number of global firsts
£80,807 1,063.75
Effect on flowthrough funding
-
£0
£0
Mapping has been changed to reflect actual LCRN support for sites within the CCG
-
£0
£0
Mapping has been changed to reflect actual LCRN support for sites within the CCG
2
£9,413
£6,000
The sites were acquired by Frimley Health NHS Foundation Trust in October 2014. In the 2015/16 funding model, no adjustment was made to recruitment figures (i.e. Heatherwood and Wexham Park recruitment was allocated to CRN: Thames Valley and South Midlands). However, it was agreed directly between the two LCRNs that £180,000 of Core funding, and £60,420 of Network RCF should be transferred from the funding allocation of CRN: Thames Valley and South Midlands to CRN: Kent, Surrey and Sussex - this will be shown as a separate adjustment in the public version of the 2015/16 funding model.
Number of study sites achieving recruitment to time and target
-
£31,753 418.00
-
£162,070 2,133.50
Effect on LCRN Performance Premium / Capacity building funding (pre MFF and cap and collar)
-
Comment
43
NIHR LCRN Funding Allocations 2016/17 Public Version
Fairbairn House 71-75 Clarendon Road Leeds LS2 9PH Tel: 0113 343 2314 Web: www.crn.nihr.ac.uk
NIHR LCRN Funding Allocations 2016/17 Public Version
Fairbairn House 71-75 Clarendon Road Leeds LS2 9PH Tel: 0113 343 2314 Web: www.crn.nihr.ac.uk
